IgA Nephropathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
IgA Nephropathy Clinical Trials Market Report Overview
The IgA Nephropathy clinical trial market research report provides an overview of the IgA Nephropathy clinical trials scenario. The report provides top-line data relating to the clinical trials on IgA Nephropathy. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Key Regions | North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America |
Key Countries | China, the US, Japan, South Korea, the United Kingdom, Spain, Australia, Italy, Germany, and Canada |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Calliditas Therapeutics AB, AstraZeneca Plc, Chinook Therapeutics Inc, Novartis AG, Syneos Health Inc, Travere Therapeutics Inc, Thermo Fisher Scientific Inc, Otsuka Holdings Co Ltd, IQVIA Holdings Inc, and F. Hoffmann-La Roche Ltd |
IgA Nephropathy Clinical Trials Market Segmentation by Regions and Countries
The key regions in the IgA Nephropathy clinical trials market are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America among others. As of April 2023, majority of the clinical trials were conducted in Asia-Pacific, followed by North America and Europe.
China, the US, Japan, South Korea, the United Kingdom, Spain, Australia, Italy, Germany, and Canada are some of the key countries in the IgA Nephropathy clinical trials market. In the country-wise analysis, China has the highest number of IgA Nephropathy clinical trials, as of April 2023, followed by the US and Japan.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the UK has the highest proportion of IgA Nephropathy to Genito Urinary System and Sex Hormones clinical trials as of April 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, China has the highest proportion of IgA Nephropathy to Genito Urinary System and Sex Hormones clinical trials as of April 2023.
IgA Nephropathy Clinical Trials Analysis by Regions, 2023 (%) For more regional insights into the IgA Nephropathy clinical trials market, download a free report sample
IgA Nephropathy Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the IgA Nephropathy clinical trials market are institution, company, and the government. Out of them, most of the trials have been sponsored by institution followed by company.
IgA Nephropathy Clinical Trials Market Analysis by Sponsor Types, 2023 (%) For more sponsor type insights into the IgA Nephropathy clinical trials market, download a free report sample
IgA Nephropathy Clinical Trials Market - Competitive Landscape
The leading sponsors in the IgA Nephropathy clinical trials market are Calliditas Therapeutics AB, AstraZeneca Plc, Chinook Therapeutics Inc, Novartis AG, Syneos Health Inc, Travere Therapeutics Inc, Thermo Fisher Scientific Inc, Otsuka Holdings Co Ltd, IQVIA Holdings Inc, and F. Hoffmann-La Roche Ltd among others. As of April 2023, Calliditas Therapeutics AB sponsored the highest number of IgA Nephropathy trials.
IgA Nephropathy Clinical Trials Market Analysis by Sponsors, 2023 (%)To know more about the leading players in the IgA Nephropathy clinical trials market, download a free report sample
Segments Covered in the Report
IgA Nephropathy Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
IgA Nephropathy Clinical Trials Country Outlook (2023)
- China
- The US
- Japan
- South Korea
- Spain
- Others
IgA Nephropathy Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies regarding investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Calliditas Therapeutics AB
Chinook Therapeutics Inc
Novartis AG
Syneos Health Inc
IQVIA Holdings Inc
Otsuka Holdings Co Ltd
Thermo Fisher Scientific Inc
Travere Therapeutics Inc
F. Hoffmann-La Roche Ltd
Table of Contents
Frequently asked questions
-
Which is the dominant region in the IgA Nephropathy clinical trials market?
Asia-Pacific dominated the IgA Nephropathy clinical trials market.
-
Which country had the highest number of iga nephropathy (berger's disease) clinical trials ?
China accounted for the highest IgA Nephropathy clinical trials market share.
-
Which sponsor type was the most preferred in the IgA Nephropathy clinical trials market?
As of April 2023 most of the trials have been sponsored by Institution.
-
Which company was the leading sponsor in the IgA Nephropathy clinical trials market?
As of April 2023, Calliditas Therapeutics AB and AstraZeneca Plc sponsored the highest number of iga nephropathy (berger’s disease) clinical trials.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more IgA Nephropathy (Berger's Disease) reports

